Logo image of DBD

DIEBOLD NIXDORF INC (DBD) Stock Fundamental Analysis

NYSE:DBD - New York Stock Exchange, Inc. - US2536512021 - Common Stock - Currency: USD

44.41  -0.46 (-1.03%)

After market: 44.41 0 (0%)

Fundamental Rating

4

Taking everything into account, DBD scores 4 out of 10 in our fundamental rating. DBD was compared to 32 industry peers in the Technology Hardware, Storage & Peripherals industry. While DBD is still in line with the averages on profitability rating, there are concerns on its financial health. DBD is valued quite cheap, while showing a decent growth score. This is a good combination!


Dividend Valuation Growth Profitability Health

Quickly go to:

4

1. Profitability

1.1 Basic Checks

DBD had positive earnings in the past year.
DBD had a positive operating cash flow in the past year.
In the past 5 years DBD reported 4 times negative net income.
The reported operating cash flow has been mixed in the past 5 years: DBD reported negative operating cash flow in multiple years.
DBD Yearly Net Income VS EBIT VS OCF VS FCFDBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 500M -500M 1B

1.2 Ratios

The Return On Assets of DBD (0.57%) is comparable to the rest of the industry.
DBD's Return On Equity of 2.08% is fine compared to the rest of the industry. DBD outperforms 64.52% of its industry peers.
DBD has a Return On Invested Capital of 8.90%. This is in the better half of the industry: DBD outperforms 64.52% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DBD is significantly below the industry average of 17.13%.
The 3 year average ROIC (4.34%) for DBD is below the current ROIC(8.90%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.57%
ROE 2.08%
ROIC 8.9%
ROA(3y)3.95%
ROA(5y)-0.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)4.34%
ROIC(5y)4.03%
DBD Yearly ROA, ROE, ROICDBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 100 200 300

1.3 Margins

The Profit Margin of DBD (0.58%) is comparable to the rest of the industry.
The Operating Margin of DBD (7.68%) is better than 64.52% of its industry peers.
In the last couple of years the Operating Margin of DBD has grown nicely.
The Gross Margin of DBD (24.64%) is worse than 64.52% of its industry peers.
DBD's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.68%
PM (TTM) 0.58%
GM 24.64%
OM growth 3Y7.99%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.9%
GM growth 5Y3.02%
DBD Yearly Profit, Operating, Gross MarginsDBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10 -10 20 30

More info and screens

2

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), DBD is creating some value.
There is no outstanding debt for DBD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
DBD Yearly Shares OutstandingDBD Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M
DBD Yearly Total Debt VS Total AssetsDBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 1B 2B 3B 4B 5B

2.2 Solvency

Based on the Altman-Z score of 1.76, we must say that DBD is in the distress zone and has some risk of bankruptcy.
DBD's Altman-Z score of 1.76 is on the low side compared to the rest of the industry. DBD is outperformed by 61.29% of its industry peers.
DBD has a debt to FCF ratio of 11.33. This is a negative value and a sign of low solvency as DBD would need 11.33 years to pay back of all of its debts.
DBD has a Debt to FCF ratio (11.33) which is in line with its industry peers.
DBD has a Debt/Equity ratio of 1.03. This is a high value indicating a heavy dependency on external financing.
DBD has a worse Debt to Equity ratio (1.03) than 61.29% of its industry peers.
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF 11.33
Altman-Z 1.76
ROIC/WACC1.27
WACC7.02%
DBD Yearly LT Debt VS Equity VS FCFDBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 1B -1B 2B

2.3 Liquidity

DBD has a Current Ratio of 1.45. This is a normal value and indicates that DBD is financially healthy and should not expect problems in meeting its short term obligations.
DBD's Current ratio of 1.45 is in line compared to the rest of the industry. DBD outperforms 45.16% of its industry peers.
DBD has a Quick Ratio of 1.45. This is a bad value and indicates that DBD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of DBD (0.96) is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 1.45
Quick Ratio 0.96
DBD Yearly Current Assets VS Current LiabilitesDBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 500M 1B 1.5B 2B 2.5B

More info and screens

4

3. Growth

3.1 Past

DBD shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 997.67%, which is quite impressive.
Measured over the past years, DBD shows a very strong growth in Earnings Per Share. The EPS has been growing by 69.69% on average per year.
EPS 1Y (TTM)997.67%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-67.88%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.74%

3.2 Future

Based on estimates for the next years, DBD will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.26% on average per year.
The Revenue is expected to grow by 1.31% on average over the next years.
EPS Next Y18.92%
EPS Next 2Y18.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1%
Revenue Next 2Y1.31%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
DBD Yearly Revenue VS EstimatesDBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 1B 2B 3B 4B
DBD Yearly EPS VS EstimatesDBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 2 -2 4

More info and screens

8

4. Valuation

4.1 Price/Earnings Ratio

DBD is valuated reasonably with a Price/Earnings ratio of 11.51.
Compared to the rest of the industry, the Price/Earnings ratio of DBD indicates a rather cheap valuation: DBD is cheaper than 83.87% of the companies listed in the same industry.
DBD's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 29.63.
Based on the Price/Forward Earnings ratio of 9.67, the valuation of DBD can be described as reasonable.
Based on the Price/Forward Earnings ratio, DBD is valued cheaper than 83.87% of the companies in the same industry.
DBD's Price/Forward Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 22.68.
Industry RankSector Rank
PE 11.51
Fwd PE 9.67
DBD Price Earnings VS Forward Price EarningsDBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, DBD is valued cheaper than 96.77% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, DBD is valued cheaper than 80.65% of the companies in the same industry.
Industry RankSector Rank
P/FCF 17.19
EV/EBITDA 5.93
DBD Per share dataDBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60 80 100

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
DBD's earnings are expected to grow with 18.26% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.61
PEG (5Y)N/A
EPS Next 2Y18.26%
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for DBD!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

DIEBOLD NIXDORF INC

NYSE:DBD (2/21/2025, 8:12:09 PM)

After market: 44.41 0 (0%)

44.41

-0.46 (-1.03%)

Chartmill FA Rating
GICS SectorInformation Technology
GICS IndustryGroupTechnology Hardware & Equipment
GICS IndustryTechnology Hardware, Storage & Peripherals
Earnings (Last)02-12 2025-02-12/bmo
Earnings (Next)04-30 2025-04-30/bmo
Inst Owners102.4%
Inst Owner Change-0.67%
Ins Owners1.65%
Ins Owner Change0.22%
Market Cap1.67B
Analysts83.33
Price Target63.75 (43.55%)
Short Float %2.23%
Short Ratio7.25
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-21.86%
Min EPS beat(2)-52.17%
Max EPS beat(2)8.44%
EPS beat(4)3
Avg EPS beat(4)118.34%
Min EPS beat(4)-52.17%
Max EPS beat(4)407.85%
EPS beat(8)5
Avg EPS beat(8)-120.62%
EPS beat(12)6
Avg EPS beat(12)-123.01%
EPS beat(16)8
Avg EPS beat(16)-94.49%
Revenue beat(2)1
Avg Revenue beat(2)0.3%
Min Revenue beat(2)-1.24%
Max Revenue beat(2)1.85%
Revenue beat(4)3
Avg Revenue beat(4)0.47%
Min Revenue beat(4)-1.24%
Max Revenue beat(4)1.85%
Revenue beat(8)3
Avg Revenue beat(8)-0.94%
Revenue beat(12)3
Avg Revenue beat(12)-2.49%
Revenue beat(16)4
Avg Revenue beat(16)-2.47%
PT rev (1m)0%
PT rev (3m)8.7%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-13.53%
EPS NY rev (1m)-8.09%
EPS NY rev (3m)-35.44%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-0.13%
Valuation
Industry RankSector Rank
PE 11.51
Fwd PE 9.67
P/S 0.44
P/FCF 17.19
P/OCF 14.44
P/B 1.57
P/tB N/A
EV/EBITDA 5.93
EPS(TTM)3.86
EY8.69%
EPS(NY)4.59
Fwd EY10.34%
FCF(TTM)2.58
FCFY5.82%
OCF(TTM)3.08
OCFY6.93%
SpS101.09
BVpS28.37
TBVpS-10.62
PEG (NY)0.61
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.57%
ROE 2.08%
ROCE 11.26%
ROIC 8.9%
ROICexc 9.9%
ROICexgc 26.74%
OM 7.68%
PM (TTM) 0.58%
GM 24.64%
FCFM 2.56%
ROA(3y)3.95%
ROA(5y)-0.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)4.34%
ROIC(5y)4.03%
ROICexc(3y)5.63%
ROICexc(5y)5.08%
ROICexgc(3y)27.53%
ROICexgc(5y)22.99%
ROCE(3y)5.5%
ROCE(5y)5.1%
ROICexcg growth 3Y-10.37%
ROICexcg growth 5YN/A
ROICexc growth 3Y-2.83%
ROICexc growth 5YN/A
OM growth 3Y7.99%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-4.9%
GM growth 5Y3.02%
F-Score6
Asset Turnover0.97
Health
Industry RankSector Rank
Debt/Equity 1.03
Debt/FCF 11.33
Debt/EBITDA 2.59
Cap/Depr 14%
Cap/Sales 0.49%
Interest Coverage 250
Cash Conversion 27.28%
Profit Quality 437.39%
Current Ratio 1.45
Quick Ratio 0.96
Altman-Z 1.76
F-Score6
WACC7.02%
ROIC/WACC1.27
Cap/Depr(3y)17.06%
Cap/Depr(5y)17.08%
Cap/Sales(3y)0.63%
Cap/Sales(5y)0.71%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)997.67%
EPS 3Y69.69%
EPS 5YN/A
EPS Q2Q%-67.88%
EPS Next Y18.92%
EPS Next 2Y18.26%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-4.74%
Revenue Next Year1%
Revenue Next 2Y1.31%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y168.6%
EBIT growth 3Y6.66%
EBIT growth 5YN/A
EBIT Next Year37.4%
EBIT Next 3Y16.45%
EBIT Next 5YN/A
FCF growth 1Y206.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y269.25%
OCF growth 3YN/A
OCF growth 5YN/A